

**PRODUCTIVIDAD Y VISIBILIDAD DE LA
INVESTIGACION
DE LA FACULTAD DE MEDICINA DE LA
UNIVERSIDAD COMPLUTENSE DE MADRID.**

2017



Universidad
Complutense
Madrid

Vicedecanato de Investigación

Método

ISI Web of Science

Tipo de documento: Artículo, review, proceeding paper, letter

Dirección: Complutense y Medicina

Web of Science®

Address=(complutense same med*) or (UCM same med*)

Timespan=2017.

Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC.

Herramientas de la propia base de datos: “Citation Report” y “Analyze Results”:

Año de publicación (Publication year).

Área (Subject Area).

Nombre de la revista (Source title).

Autor (Author).


Idioma (language).

PRODUCCION CIENTÍFICA 2017

689 DOCUMENTOS

| | |
|-------------------|-----|
| ARTICLE | 575 |
| REVIEW | 61 |
| LETTER | 43 |
| PROCEEDINGS PAPER | 16 |

| | |
|---------|-----|
| ENGLISH | 625 |
| SPANISH | 64 |



ÁREAS MÁS PRODUCTIVAS

| | |
|-----------------------------------|----|
| CARDIAC CARDIOVASCULAR SYSTEMS | 47 |
| MICROBIOLOGY | 47 |
| NEUROSCIENCES | 47 |
| PHARMACOLOGY PHARMACY | 47 |
| MULTIDISCIPLINARY SCIENCES | 46 |
| CLINICAL NEUROLOGY* | 42 |
| PSYCHIATRY | 31 |
| INFECTIOUS DISEASES | 30 |
| IMMUNOLOGY | 28 |
| ONCOLOGY* | 27 |

ÁUTORES MÁS PRODUCTIVOS

| | |
|--------------------|----|
| BOUZA E | 37 |
| MUNOZ P | 18 |
| ARANGO C | 16 |
| BENITO-LEON J | 15 |
| LOPEZ-HERCE J | 14 |
| FERNANDEZ-AVILES F | 12 |
| REGIDOR E | 12 |
| ARROYO-PARDO E | 11 |
| GOMES C | 11 |
| GUINEA J | 11 |



Perez et al. (**Martin, M**) Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. JOURNAL OF CLINICAL ONCOLOGY

Paz-Ares et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial ANNALS OF ONCOLOGY

Sordo, L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies BRITISH MEDICAL JOURNAL

Calleja, JL et al. (**Rincon D, Banares, R**). Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. JOURNAL OF HEPATOLOGY

Prince et al. (**Ortiz-Romero, PL**) Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial LANCET

Martin, M et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4) ANNALS OF ONCOLOGY

Dondo et al. (**Bueno, H**). beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Calle-Rubio, MC et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Aleman et al. (**Arango, C**) Treatment of negative symptoms: Where do we stand, and where do we go? SCHIZOPHRENIA RESEARCH

OTRAS PUBLICACIONES DESTACABLES

NATURE Olmeda et al. (**Riveiro-Falkenbach, E; Ortiz-Romero, P; Rodríguez-Peralto**) Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

NATURE NEUROSCIENCE Lim, E et al. (**Arango, C**) Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder


CIRCULATION **Perez de Isla, L et al.**, Predicting Cardiovascular Events in Familial Hypercholesterolemia The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)

BLOOD Fulciniti et al., (**Martinez-Lopez, J**) Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

JOURNAL OF EXPERIMENTAL MEDICINE. Hosomi et al. (**Martinez-Naves, E del Moral, MG**). Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation.


PRODUCCION INVISIBLE

Producción de los hospitales asociados




Evolución en porcentaje de la producción de los hospitales en la que consta la UCM y/o la Facultad de Medicina UCM

UCM y Medicina



UCM



OTRAS PUBLICACIONES DESTACABLES INVISIBLES

(UCM no Med)

LANCET Soria et al (Paz-Ares L) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

NEW ENGLAND JOURNAL OF MEDICINE. Carbone, DP (Paz-Ares L) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Antonia (Paz-Ares L) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Wilcox et al. (Bouza, E) Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

NEW ENGLAND JOURNAL OF MEDICINE. (Escaned J) Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI

LANCET Fellstrom et al., (Praga, M) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

(No UCM)

NEW ENGLAND JOURNAL OF MEDICINE. Fizzazi et al (Rodríguez-Antolin) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

LANCET (Paz-Ares L) Lung cancer: current therapies and new targeted treatments

Contribución de la producción de Facultad a la UCM

22 de las 36



Highly Cited Paper

24% de la producción real de la UCM se corresponde con la Facultad o los hospitales (2561 de 4430 documentos).

EVALUACION DE GRUPOS PROVISIONAL UCM (AEI)

| | |
|------------------|-----------|
| Evaluados | 34 |
| Cuestionables | 2 |
| Aceptables | 14 |
| Buenos | 11 |
| Excelentes | 6 |

EXCELENTES

Investigadores Principales

R.M. Ayala

J. Tamargo y E. Delpón

F. Pérez-Vizcaíno y A. Cogolludo

M.J. Recio, P. Roda

J.C. Leza

I. Lizasoain y M.A. Moro

J. Fernández-Ruiz

*Departamento de XXXX, **Facultad de Medicina**,
Universidad Complutense de Madrid

*Department of XXXX, **School of Medicine**,
Universidad Complutense de Madrid

Ejemplo:

Garcia-Garcia A^{1,2,3}

¹Department of Medicine, **School of Medicine**,
Universidad Complutense de Madrid, Spain.

²Instituto de Investigación Sanitaria San Carlos
(IdISSC).

³Ciber de Enfermedades Respiratorias (Ciberes).